Bio-Gate AG
0.57
EUR
+0.02
(+2.73%)
ISIN
DE000BGAG981
Return %
Stock
S&P 500
1Y
-43.50
14.20
3Y
-56.87
81.12
5Y
-88.23
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Marc Lloret-Grau
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nuremberg Germany
- IPO Date
- Apr 5, 2006
- Website
- bio-gate.de
- Similar Companies
- Business
- Bio-Gate AG is a Germany-based medical technology and biotechnology company that develops, manufactures, and markets antimicrobial and antiviral surface coatings, material enhancements, and hygiene technologies. Founded in 2000 and headquartered in Nuremberg, Germany, the company operates across five primary business segments: Medical Technology, Dermacosmetics, Wound Care, Veterinary Medicine, and Industrial Solutions, while also providing specialized contract laboratory testing through its wholly owned subsidiary, QualityLabs BT GmbH. The company's core product and technology portfolio encompasses MicroSilver BG, a pure, porous, elemental micro-silver additive utilized as an active antimicrobial ingredient across dermatological skincare formulations, oral care products, wound dressings, veterinary topicals, and polymer materials; HyProtect, an ultrathin, silver-bearing polysiloxane plasma coating applied to orthopedic revision prostheses, trauma implants, dental devices, and surgical meshes to inhibit bacterial adhesion and prevent implant-associated infections; Dermacosmetic Formulations, consisting of specialized creams, lotions, and barrier-repair skincare products designed for sensitive and damaged skin; Veterinary Care Solutions, comprising targeted topical sprays, ear cleansing solutions, and wound balms for companion animals and livestock; Industrial Additives and Surface Treatments, including antimicrobial masterbatches and liquid dispersions tailored for incorporation into plastics, textiles, and functional coatings; and Microbiological Laboratory Services, delivering certified testing, anti-adhesive surface characterization, and proprietary CERTIKA proliferation assay evaluations for medical device manufacturers and industrial clients. Bio-Gate AG serves medical device corporations, pharmaceutical distributors, cosmetic brands, veterinary suppliers, and industrial manufacturers across Europe, North America, and other international regions, operating in North American markets through distribution and representative partnerships including RFH BioTek Inc. In recent developments, Bio-Gate AG expanded its commercial alliances, clinical programs, and capitalization to drive operational growth. The company extended its long-term collaboration with custom implant manufacturer OSSIS following OSSIS's acquisition by global orthopedic corporation Zimmer Biomet, broadening international market access for HyProtect-coated revision implants. Within its veterinary segment, Bio-Gate entered strategic commercial agreements with North American animal health providers to launch dedicated skin and wound care lines. In addition, the company initiated multicenter clinical trials to advance regulatory certification and adoption of its HyProtect hip revision implant coatings, and executed corporate capital increases to reinforce its balance sheet and support expanded clinical development and international commercialization efforts.